Page 252 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

Index

Note: Page numbers followed by “f” indicate figures, “t” indicate tables.
A Antibody-drug conjugate (ADC), 76
Abnormal acetylation, 57 antigens, 90
Abscopal effect, 81f antobodies, 91
Acetylation, 57 drugs, 93
Acoustophoresis technology, 183 linkers and conjugates, 92
ACT. See adoptive cell therapy (ACT) Anticancer antibodies, 46
Active micromixers, 228 Anti-CTLA-4. See anticytotoxic T lymphocyte-
Acute lymphoblastic leukemia (ALL), 89 associated antigen 4
Acute myeloid leukemia (AML), 88, 123 (anti-CTLA-4)
ADC. See antibody-drug conjugate (ADC) Anticytotoxic T lymphocyte-associated antigen 4
ADCC. See Antibody dependent cellular (anti-CTLA-4), 3
cytotoxicity (ADCC) Antigens, in cancer stem cells, 91
Adoptive cell therapy (ACT), 115 Anti-PD1 monoclonal antibody (mAb), 3
chimeric antigen receptors, 73 Anti-prostate-specific membrane antigen, 77
in combination with chemotherapy Antitumor immunity, 70
chimeric antigen receptor T cell therapy, 117 Antobodies, 91
dendritic cell-based therapy, 119 Artificial APCs, 73
T cell receptor, cancer therapy with, 117 AR-V7. See androgen-receptor splice variant 7
tumor-infiltrating lymphocytes, cancer (AR-V7)
therapy with, 116 ATC. See anaplastic thyroid cancer (ATC)
endogenous T cell, 73 Autoantibodies, 49
Adoptive T-cell therapy, 4 associated with cancer detection, 49t
Adult stem cells, 124 Autologous APCs, 73
A-fetoprotein (AFP), detection of cancer markers,
59 B
AFP. See a-fetoprotein (AFP) Beads washing, 231
ALL. See acute lymphoblastic leukemia (ALL) Beer-Lambert law, 24
Allogeneic bone marrow transplantation, 4 Bernoulli equations, fluid mechanics, 11
AML. See acute myeloid leukemia (AML) Bioengineering assisted cancer
Analytical protein array, 52 imaging using nonbiological components, 8
Anaplastic thyroid cancer (ATC), 124 treatment using nonbiological components, 9
Androgen-receptor splice variant 7 (AR-V7), 63 Biomaterials, in delivery and targeting, 101
Angle blurring, 39 Biosensor, 58
Antibody Bismuth germinate crystal, 39
based targeted therapy Blockade of immune checkpoints
clinical examinations, 79 cytotoxic T lymphocyte antigen 4
immunoconjugates and unconjugated (CTLA-4), 71
antibody, 78 programmed cell death (PD-1), 71
mechanism of, 75 Bystander killing, 89
whole antibody or antibody fragments, 77
fragments, 77
immunosensors, 58 C
microarray Cancer
posttranslational modifications and its role adoptive cell therapy, 72
in cancer diagnosis, 55 blockade of immune checkpoints, 70
Antibody dependent cellular cytotoxicity (ADCC), oncolytic viral therapy, 72
75 tumor infiltrating lymphocyte, 74
251